Featured Research

from universities, journals, and other organizations

No support for routine prostate screening, but one-off test at 60 may be beneficial

Date:
September 14, 2010
Source:
BMJ-British Medical Journal
Summary:
Existing evidence from randomized controlled trials does not support routine population screening for prostate cancer, a new study concludes. However, a second study suggests that a single test at age 60 could identify men who are most likely to develop and die from prostate cancer. These men could then be monitored more closely, while others could be exempt from further screening.

Existing evidence from randomised controlled trials does not support routine population screening for prostate cancer, concludes a study published online in the British Medical Journal.

However, a second study suggests that a single test at age 60 could identify men who are most likely to develop and die from prostate cancer. These men could then be monitored more closely, while others could be exempt from further screening.

Prostate cancer is one of the most common cancers among men worldwide. Screening is widely used in many countries, but it remains controversial because experts can't agree whether the benefits of screening outweigh the potential harms and costs of over-diagnosis and over-treatment of healthy men.

In 2006, a review of two randomised controlled trials concluded that there was not enough evidence to support routine prostate cancer screening. Since then, four new trials have been published.

So Professor Philipp Dahm and colleagues at the University of Florida reviewed all six trials, involving 387,286 participants. They found that screening aids in the diagnosis of prostate cancer at an earlier stage, but does not have a significant impact on mortality, and comes at the risk of over-treatment.

The authors say there is insufficient evidence to support actively inviting all men in certain age groups to attend screening for prostate cancer (as happens with breast cancer screening for women), and they suggest men should be better informed about the uncertainties associated with screening.

In the second study, Professor Hans Lilja and colleagues show that a single prostate-specific antigen (PSA) level test at age 60 strongly predicts a man's lifetime risk of diagnosis and death from prostate cancer.

They found that 90% of prostate cancer deaths occurred in men with highest PSA levels at age 60, whereas men with average or low PSA levels had negligible rates of prostate cancer or death by age 85. Their results suggest that at least half of men aged 60 and older might be exempted from further prostate cancer screening, which would reduce over-diagnosis and over-treatment.

In an accompanying editorial, Gerald Andriole, Chief of Urologic Surgery at Washington University School of Medicine, suggests that PSA testing should be tailored to individual risk.

He recommends that young men at high risk of prostate cancer, such as those with a strong family history and higher baseline PSA concentrations, should be followed closely, while elderly men and those with a low risk of disease could be tested less often, if at all. "Approaches such as these will hopefully make the next 20 years of PSA based screening better than the first 20," he says.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "No support for routine prostate screening, but one-off test at 60 may be beneficial." ScienceDaily. ScienceDaily, 14 September 2010. <www.sciencedaily.com/releases/2010/09/100914191650.htm>.
BMJ-British Medical Journal. (2010, September 14). No support for routine prostate screening, but one-off test at 60 may be beneficial. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2010/09/100914191650.htm
BMJ-British Medical Journal. "No support for routine prostate screening, but one-off test at 60 may be beneficial." ScienceDaily. www.sciencedaily.com/releases/2010/09/100914191650.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins